Showing 7911-7920 of 9549 results for "".
- Face Reality Skincare Partners with Olympic Swimming Medalist Abbey Weitzeilhttps://practicaldermatology.com/news/face-reality-skincare-partners-with-olympic-swimming-medalist-abbey-weitzeil/2460847/
- OMNY Health Launches Integrated Dermatology Data Repository and Research Networkhttps://practicaldermatology.com/news/omny-health-launches-integrated-dermatology-data-repository-and-research-network/2460845/OMNY Health has partnered with community-based dermatology practices to create a first-of-a-kind integrated, normalized, de-identified electronic health record (EHR) data repository for dermatological research. The assembled longitudinal data represents care delivered over the pas
- Nutrafol Launches Postpartum Formulahttps://practicaldermatology.com/news/nutrafol-launches-postpartum-formula/2460838/The first-of-its-kind postpartum hair nutraceutical is now available from Nutrafol. Nutrafol Postpartum was developed with an OB/GYN to target the root causes of excess hair shedding and thinning post-pregnancy. It is intended to help the body recover from the physical stress of childbirth,
- BioFactura Starts Phase I Study of BFI-751, a Stelara Biosimilarhttps://practicaldermatology.com/news/biofactura-starts-phase-i-study-of-bfi-751-a-stelara-biosimilar/2460811/BioFactura is set to begin a pivotal pharmacokinetics Phase 1 clinical trial for its Ustekinumab biosimilar BFI-751. The first-in-human Phase I study will assess the effects on healthy human volunteers compared to the biologic medicine, Stelara. This is the first time BFI-751 has been a
- FDA Nod for Modifications to Soliton's Resonic Devicehttps://practicaldermatology.com/news/fda-nod-for-modifications-to-solitons-tattoo-removal-device/2460790/The U.S. Food and Drug Administration granted Soliton, Inc. 510(k) for modifications to its RESONIC device. The RESONIC device utilizes the RAP technology to deliver safe and effective tattoo removal and cellulite treatment and now includes an autoloading cartridge and an
- Potential Regenerative Medicine Breakthrough: Mayo Clinic Preclinical Discovery Triggers Scar-free Wound Healinghttps://practicaldermatology.com/news/potential-regenerative-medicine-breakthrough-mayo-clinic-preclinical-discovery-triggers-scar-free-wound-healing/2460788/Difficult-to-treat, chronic wounds in preclinical models healed with normal scar-free skin after treatment with an acellular product discovered at Mayo Clinic. Derived from platelets, the purified exosomal product, known as PEP, was used to deliver healing messages into cells of p
- Skin Cancer Foundation Champions for Change Gala Goes Virtualhttps://practicaldermatology.com/news/skin-cancer-foundation-champions-for-change-gala-goes-virtual/2460783/The Champions for Change Gala, the Skin Cancer Foundation’s signature fundraising event, be held virtually, Tuesday, May 11. Proceeds from the annual event support the organization’s educational campaigns, community programs, and research initiatives. The event will be
- Sirnaomics Starts Phase 2b Study of STP705 for SCChttps://practicaldermatology.com/news/sirnaomics-inc-starts-phase-2b-study-of-stp705-for-scc/2460778/Sirnaomics, Inc. is initiating a Phase 2b study of STP705 for the treatment of squamous cell skin cancer. STP705 is a siRNA (small interfering RNA) therapeutic that takes advantage of a dual-targeted inhibitory property and polypeptide nanoparticle (PNP)-enhanced delivery
- Visible Light from the Sun Causes Pigmentary Skin Changeshttps://practicaldermatology.com/news/visible-light-from-the-sun-causes-pigmentary-skin-changes/2460768/Visible light from the sun plays a significant role in causing pigmentary skin changes, particularly in people with skin of color, according to information presented at AAD VMX 2021. “We know from decades of research that unprotected exposure to ultraviolet light from the sun can
- Roflumilast Foam and Cream Show Promise in Multiple Skin Diseaseshttps://practicaldermatology.com/news/roflumilast-foam-and-cream-show-promise-in-multiple-skin-diseases/2460767/Roflumilast foam significantly improved both scalp and body psoriasis, with improvement as early as two weeks after treatment initiation, data presented at the 2021 AAD VMX show. Additionally, data presented in posters at the AAD VMX show that roflumilast foam is a safe, well-tolerated, and effec